USPTO 2015–2025 USPTO PatentsView US Corporation

Allergan, Inc.

USPTO PatentsView assignee record - 612 granted patents across 57 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company

The verdict

According to USPTO PatentsView, Allergan ranks #745 of 49,997 tracked US assignees by granted-patent volume, with 612 patents across 57 technology areas.

#745
of 49,997 US assignees by volume
Top 7%
by Innovation Score (55.5/100)
11.5
avg claims per patent
-75%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R745 · US Corporation #745 · 612 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-WIDE · INNOV-PAR · CLAIMS-PAR · TYPE-USCORP · VEL-DROP · BOOK-FULL

  • GRANTS-MID 612 grants
  • TOP-DECILE #745/49,997
  • PHOTO-FINISH Ford Motor
  • CPC-WIDE A61P · 57 areas
  • INNOV-PAR 55.5/100
  • CLAIMS-PAR 11.5 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-DROP -75% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Ford Motor Company (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Allergan

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Allergan's Innovation Score is 55.5/100 (top 7% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

How Allergan's grant cadence moved

Between 2020–2024, Allergan, Inc. received 120 grants versus 489 in 2015–2019 (-75% equal-window velocity, below median growth). Across complete PatentsView years, output peaked in 2015 at 141 grants and bottomed in 2023 at 7. Lead class A61P accounts for 67.8% of the portfolio across 57 subclasses. Volume neighbours: Suzuki Motor Corporation (#741) and Renault S.A.S. (#749).

Allergan's three-year grant acceleration

From 2019–2021 to 2022–2024, Allergan, Inc. moved from 156 to 32 grants (0.20x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #3,086. See the growth leaderboard.

Who files at Allergan's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Allergan holds 612 patents at rank #745, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Allergan

By rank, the assignees closest to #745 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Allergan's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Allergan, neither rank-band nor same-CPC leaders (those blocks stay above).

Allergan's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

55 Top 7% higher than 93% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

050100150 20152016201720182019202020212022202320242025 3
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Allergan, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 141 23.0%
2016 125 20.4%
2017 95 15.5%
2018 60 9.8%
2019 68 11.1%
2020 50 8.2%
2021 38 6.2%
2022 17 2.8%
2023 7 1.1%
2024 8 1.3%
2025partial year 3 0.5%

Which technologies does Allergan, Inc. patent most?

Top 15 of 57 technology areas

Where it ranks

Overall rank by patents

#745

of 49,997 tracked assignees

Innovation Score

55.5 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Allergan, Inc.'s patent record in context - here's where to go next.

  • Allergan, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 67.8% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #745 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Allergan, Inc. against Suzuki Motor Corporation, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 55.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.